Pliant Therapeutics reports positive Phase 2a INTEGRIS-PSC data for bexotegrast in PSC

PLIANT THERAPEUTICS, INC.

Trial met primary safety endpoint; bexotegrast well tolerated with 94% completing 12 weeks, no drug-related SAEs.
Exploratory efficacy: significant reduction in ELF score and PRO-C3 at 160 mg vs placebo at Week 12.
Dose-dependent trend in ALP reduction; MRI imaging suggests improved hepatocyte function and bile flow.
High-dose 320 mg interim data expected Q1 2024; full 24-week data mid-2024.
Company to host webcast today at 8:00 AM ET to discuss results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.